Skip to main
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 0%
Hold 67%
Sell 17%
Strong Sell 0%

Bulls say

Amphastar Pharma is well positioned for continued growth because management still expects 2026 high-single-digit top-line expansion even after a downward revision to Baqsimi, signaling resilience in the broader portfolio. The company also expects Baqsimi margins to improve by discontinuing a small amount of international sales starting in 2H26, while peak sales expectations of $250MM-$275MM remain unchanged, supporting profitability and visibility. In addition, the recent launch of ipratropium bromide HFA has not faced additional competition and could become a $30MM-$40MM sales opportunity, reinforcing a constructive outlook.

Bears say

Amphastar Pharma is facing a weak fundamental setup because Baqsimi, its flagship product, is under sustained pricing pressure from higher rebates, 340B pharmacy discounts, and an unfavorable channel mix, with 1Q26 sales falling to $32.4M from $38.4M in 1Q25 and 2Q26 sales slipping to $45.5M from $46.7M in 2Q25 despite prescription growth. Competitive erosion is also weighing on the base business, as injectable glucagon sales dropped 56% in 1Q26 after Viatris’ generic entered in December 2024, while glucagon and epinephrine together still represented more than 15% of 1Q26 revenue. With 1Q26 non-GAAP EPS of $0.42 versus $0.71 expected and limited visibility into pipeline catalysts until 2027, the company faces margin pressure, slower growth, and weak near-term earnings momentum.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Oct 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.